|
Bod announces progress in Aqua Phase PK Studies
|
30 June 2023 at 10:15am
|
|
BOD and Malaysian Antah Group sign Letter of Intent
|
21 June 2023 at 10:15am
|
|
Updates regarding Aqua Phase Delivery Technology
|
23 May 2023 at 10:10am
|
|
Quarterly Activities Report and Appendix 4C
|
28 April 2023 at 9:40am
|
|
Change in Chairman's role
|
24 April 2023 at 9:00am
|
|
Bod completes recruitment of Phase IIb clinical trial
|
4 April 2023 at 9:15am
|
|
Aqua Phase PK Study submitted for ethics approval
|
28 March 2023 at 8:55am
|
|
BOD reaches milestone in Schedule 3 CBD clinical trial
|
13 March 2023 at 9:20am
|
|
Change of Director's Interest Notice - David Baker
|
10 March 2023 at 9:50am
|
|
Grant of ASX Waiver
|
8 March 2023 at 12:40pm
|
|
Update on acquisition of Aqua Phase
|
7 March 2023 at 9:40am
|
|
Bod Science establishes R&D funding facility
|
6 March 2023 at 9:45am
|
|
Appendix 4D and Half Year Account
|
24 February 2023 at 10:30am
|
|
Quarterly Activities Report and Appendix 4C
|
31 January 2023 at 9:05am
|
|
Appointment of Company Secretary
|
24 January 2023 at 9:35am
|
|
Notification of cessation of securities - BOD
|
23 January 2023 at 11:40am
|
|
Bod Science receives $1.512 million R&D tax rebate
|
20 December 2022 at 9:40am
|
|
Change of Director's Interest Notice - G Livery and A Bedi
|
19 December 2022 at 6:00pm
|
|
Notification of cessation of securities - BOD
|
19 December 2022 at 5:20pm
|
|
Change of Company Name to Bod Science Limited
|
12 December 2022 at 11:40am
|
|
Appendix 3Y's - Baker, Livery, Patterson and Bedi
|
6 December 2022 at 6:25pm
|
|
Secton 708A cleansing notice
|
6 December 2022 at 10:25am
|
|
Application for quotation of securities - BOD
|
6 December 2022 at 8:50am
|
|
Bod secures licensing and supply agreement with Arrotex
|
2 December 2022 at 10:25am
|
|
Notification regarding unquoted securities - BOD
|
2 December 2022 at 8:55am
|
|
Notification regarding unquoted securities - BOD
|
2 December 2022 at 8:55am
|
|
Results of Annual General Meeting
|
28 November 2022 at 6:35pm
|
|
Chief Executive Officer presentation to the 2022 AGM
|
28 November 2022 at 2:50pm
|
|
Bod Softgel offers outstanding bioavailability
|
22 November 2022 at 10:15am
|
|
Final Director's Interest Notice
|
9 November 2022 at 9:35am
|
|
Resignation of Director
|
9 November 2022 at 9:30am
|
|
Annual Report to shareholders
|
28 October 2022 at 1:35pm
|
|
Appendix 4G and Corporate Governance Statement
|
28 October 2022 at 1:35pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 October 2022 at 1:35pm
|
|
Quarterly Activities Report and Appendix 4C
|
27 October 2022 at 9:55am
|
|
CEO presentation to South-West Connect Showcase
|
20 October 2022 at 2:35pm
|
|
International patent application filed by Bod
|
20 October 2022 at 9:35am
|
|
Date of Annual General Meeting
|
17 October 2022 at 8:55am
|
|
Section 708A(5) cleansing notice
|
14 October 2022 at 10:35am
|
|
Application for quotation of securities - BOD
|
14 October 2022 at 10:10am
|
|
Notification regarding unquoted securities - BOD
|
14 October 2022 at 10:10am
|
|
Amended Change of Director's Interest Notice - George Livery
|
13 October 2022 at 7:15pm
|
|
Change of Director's Interest Notice - David Baker
|
13 October 2022 at 4:25pm
|
|
Change of Director's Interest Notice - George Livery
|
13 October 2022 at 4:25pm
|
|
Apppendix 2A - Underwriting Offer
|
13 October 2022 at 11:20am
|
|
Sction 708A(5) secondary trading notice
|
11 October 2022 at 10:15am
|
|
Appendix 2A - Shortfall Offer
|
11 October 2022 at 10:15am
|
|
Application for quotation of securities - BOD
|
6 October 2022 at 2:00pm
|
|
Successful completion of Entitlement Offer
|
4 October 2022 at 5:55pm
|
|
Application for quotation of securities - BOD
|
30 September 2022 at 8:50am
|
